Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of a 13-valent pneumococcal conjugate vaccine in healthy children aged 7 months to 5 years
CTR20191734Phase 3Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of 13-valent pneumococcal polysaccharide conjugate vaccine in pneumococcal disease, Pneumococcal pneumonia (PP), sponsored by CanSino Biologics Inc.. Started Apr 2021; status: completed.
02
Drugs
13-valent pneumococcal polysaccharide conjugate vaccine
03
Conditions
pneumococcal diseasePneumococcal pneumonia (PP)
Beyond the preview
Go deeper on CTR20191734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191734.